LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: LabCorp is the second-largest independent clinical laboratory company in the United States. It operates a national network of 37 primary laboratories and over 1,600 patient service centers, processing more than 420,000 patient specimens daily. The company serves physicians, hospitals, managed care organizations, and government agencies with routine and specialty testing services, including oncology, HIV, and diagnostic genetics.

Key Financial Metrics (Year Ended Dec 31, 2007)

Note: Gross margin was 41.6% in 2007 compared to 42.6% in 2006. Operating margin was 19.1% in 2007 compared to 19.4% in 2006.

Material Changes vs. Prior Period

• Revenue Growth: Driven by a 12.3% increase in total test volume (accessions) and a shift in test mix toward higher-priced genomic and esoteric tests. Managed care revenue increased to 46.1% of total sales.
• Restructuring Charges: The company recorded net restructuring charges of $50.6 million in 2007, primarily for workforce reductions (1,560 employees) and facility consolidations, compared to only $1.0 million in 2006.
• Debt Structure: Long-term obligations increased significantly due to the borrowing of $500 million under a new Term Loan Facility in October 2007. This was part of a new $1 billion credit facility.
• Stock Repurchases: The company repurchased $924.2 million (13.1 million shares) of its common stock in 2007, contributing to the decrease in shareholders' equity.
• UnitedHealthcare Contract: The company began its exclusive ten-year agreement with UnitedHealthcare in 2007, incurring $32.0 million in transition payments during the year.

Guidance, Outlook, and Risks

Management Commentary & Strategy: Management focuses on three strategic priorities: scientific differentiation (genomic/advanced testing), managed care partnerships, and customer service. The company expects to continue growing its esoteric testing business, which generated $1.4 billion in revenue in 2007. Capital expenditures for 2008 are expected to be between $120 million and $140 million.

Key Risks & Contingencies:

• Reimbursement Pressure: Continued efforts by Medicare, Medicaid, and private payers to reduce costs and control utilization pose a risk to margins. The company faces potential reductions in fee schedules and increased competitive bidding.
• Regulatory Compliance: The industry is subject to extensive regulation (CLIA, HIPAA, Stark Law, Anti-Kickback). Violations could result in fines, exclusion from government programs, or loss of licensure.
• Joint Venture Consolidation: Effective January 1, 2008, the company increased its ownership in its Ontario, Canada joint venture to 85.6% and began consolidating its results, which may impact future financial reporting.
• Legal Proceedings: The company is involved in various legal actions, including patent disputes and qui tam suits under the False Claims Act, though management does not expect a material adverse effect.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the new credit facility covenants (leverage ratio of 2.5:1 and interest coverage of 5.0:1).
• UnitedHealthcare Transition Costs: Monitor the total cost of the UnitedHealthcare transition payments, which the company estimates at approximately $115 million over the first three years.
• Days Sales Outstanding (DSO): Review aging of accounts receivable, as billing complexity and payer mix changes (increased patient deductibles) could impact cash collections.
• Zero-Coupon Notes: Note the $741.2 million aggregate principal amount of zero-coupon convertible subordinated notes due 2021, which may be put to the company in 2011.
• Restructuring Execution: Track the execution of the $50.6 million restructuring plan to ensure anticipated cost savings are realized.